T-knife Therapeutics completes US$110 Million Series B financing

On August 2, 2021, T-knife Therapeutics, Inc. (“T-knife”) announced the successful completion of a US$110 million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with participation from other new investors including, LSP, Qatar Investment Authority (QIA), Casdin Capital, Sixty Degree Capital, and CaaS Capital, along with existing investors RA Capital Management, Versant Ventures and founding investor Andera Partners. The company plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor (“TCR”) engineered T cell therapies (TCR-T).

T-knife is leveraging its proprietary HuTCR transgenic mouse platform to discover and develop a portfolio of TCR-T programs to treat patients with solid tumors. T-knife’s lead program, TK-8001, is a novel TCR-T product candidate targeting MAGE-A1 positive cancers. T-knife plans to begin enrolling patients in the TK-8001 IMAG1NE Phase 1/2 clinical study in the fourth quarter of 2021 and is planning to submit INDs/CTAs for additional product candidates in 2022.

Further information can be found on Globe Newswire’s website.

T-knife is a next-generation TCR company developing a pipeline of therapeutics for solid tumor patients. T-knife is developing a pipeline of potential first/best-in-class TCR therapeutics against targets with high unmet medical need, including cancer testis antigens, viral antigens and commonly shared neoantigens.

Sixty Degree Capital invests in the evolving areas of biopharmaceuticals, healthcare platforms and technology.